US FTC suspends challenge to Amgen's deal for Horizon Therapeutics
Aug 26 (Reuters) - The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen's AMGN.O $27.8 billion purchase of Horizon Therapeutics HZNP.O , a filing late on Friday showed. (Reporting by Urvi Dugar in Bengaluru; editing by Jason Neely) ((UrviManoj.Dugar@thomsonreuters.com;))
Recent news on Horizon Therapeutics
See all newsDeals of the day-Mergers and acquisitions
Amgen completes $27.8 bln Horizon deal (updated)
Amgen completes acquisition of Horizon Therapeutics
Brief: Amgen Completes Acquisition Of Horizon Therapeutics PLC
On October 5, Court Sanctioned The Scheme Of Arrangement Under Chapter 1 Of Part 9 Of The Irish Companies Act 2014